pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
◐
Sign In
Subscribe
🐶
home
jobs
news
search
LILLY · news · pharmadog
← back to LILLY
News mentioning LILLY
309
stories
Jun 11, 26
STAT+: Pharmalittle: We’re reading about employer coverage of obesity drugs, another Sanofi setback, and more
stat
Jun 10, 26
STAT+: Pharmalittle: We’re reading about U.S. pressure on European drug prices, longer shortages, and more
stat
Jun 10, 26
AstraZeneca’s ‘extensive’ obesity drug push; $125M for ultrasound-aided genetic medicine
biopharma dive
Jun 9, 26
STAT+: The shortage of many medicines in the U.S. remains a ‘systemic’ problem, a new analysis finds
stat
Jun 9, 26
Eli Lilly's claims data deadline may kick off new 340B fight
endpoints
Jun 9, 26
Stealthy startup Treeline plans a reverse merger
biopharma dive
Jun 9, 26
Gilead and Merck’s latest trial success and flop
stat
Jun 9, 26
Lilly offers up to $1B for Alzheimer's drug; Bial cuts failed Parkinson's drug
endpoints
Jun 9, 26
STAT+: Pharmalittle: We’re reading about a $10.6 billion GSK deal, an AstraZeneca obesity pill, and more
stat
Jun 8, 26
Health workers at the epicenter of Congo’s Ebola outbreak labor with little pay or rest
stat
Jun 8, 26
STAT+: AstraZeneca’s GLP-1 pill shows promise in obesity, diabetes trials
stat
Jun 8, 26
ADA ‘26: Lilly’s dominance, Pfizer’s ‘foundational’ drug and Roche’s ‘me-too’ option
biopharma dive
Jun 8, 26
STAT+: Novo underwhelmed by drug it once fought Pfizer for
stat
Jun 8, 26
STAT+: Pharmalittle: We’re reading about Lilly and Pfizer obesity drug data, Roche and J&J deals, and more
stat
Jun 8, 26
#ADA26: Novo Nordisk targets 2030 launch for triple-G obesity shot
endpoints
Jun 8, 26
STAT+: J&J spends $1 billion to enter KRAS race for cancer treatments
stat
Jun 8, 26
Major readouts from the annual diabetes conference
stat
Jun 8, 26
STAT+: Combination of pancreatic cancer drugs from Tango, Revolution leads to high response rate
stat
Jun 8, 26
Opinion: $2 million gene therapy cures require a financing model
stat
Jun 7, 26
STAT+: New data may cast doubt on competitiveness of Boehringer’s obesity drug
stat
Jun 6, 26
STAT+: Lilly shares safety, tolerability data on its next-gen obesity drug
stat
Jun 6, 26
STAT+: Detailed data show Pfizer’s monthly obesity drug continues to show potential
stat
Jun 5, 26
Study data convince Lundbeck to push new migraine drug forward
biopharma dive
Jun 5, 26
STAT+: Pharmalittle: We’re reading about Roche accusing U.S. of ‘blackmail,’ a ruling on skinny labels, and more
stat
Jun 4, 26
STAT+: Supreme Court backs generic drugmaker in ‘skinny labeling’ case
stat
Jun 4, 26
STAT+: For pancreatic cancer patients, an exciting drug can feel out of reach
stat
Jun 4, 26
Lilly, Boehringer retrench in Germany on proposed health spending cuts
endpoints
Jun 4, 26
Alnylam, Inceptive ink AI deal potentially worth $2B
biopharma dive
Jun 4, 26
Otsuka showcases kidney drug data; Pfizer cuts an AI deal
biopharma dive
Jun 4, 26
STAT+: Pharmalittle: We’re reading about fewer pharma investments in Germany, growing U.S. layoffs, and more
stat
← prev
page 7 of 11
next →
